- Nature Communications
TG4050
TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer
Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings
Article available for the first time on Nature Communications website – Download the Article - Advancing our pipeline
Expanding myvac®
TG4050, Head and neck cancer (adjuvant) – Phase 2 ongoing
TG4070, Non-small cell lung cancer (adjuvant) – Phase 1
.
Our Individualized Therapeutic Vaccines harness the patient’s immune system to fight against disease
Last press releases (3)
- November 9, 2026Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
- November 5, 2026First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
- November 3, 2026Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
See all press releases